Office: 212 Pavilion

Phone: 412-624-4595

Fax: 412-624-1850

Email: poloyac@pitt.edu

pubmedLinkedIn

Samuel M. Poloyac, PharmD, PhD, FCCM is a Professor of Pharmaceutical Sciences and the Associate Dean for Graduate and Postdoctoral Programs at the University of Pittsburgh School of Pharmacy. Dr. Poloyac also serves as the Director of the Center for Clinical Pharmaceutical Sciences and the Director of the Small Molecule Biomarker Core Laboratory at the University of Pittsburgh. Dr. Poloyac graduated from the University of Pittsburgh with a BS in Pharmacy (1993), and then completed his PharmD (1995) and PhD (1999) degrees at the University of Kentucky.

Upon returning to the University of Pittsburgh as a faculty member (1999), Dr. Poloyac has focused on determining the role of drug metabolizing, cytochrome P450, enzymes on fatty acid bioactivation and drug disposition in the pathogenesis of disease in critically ill patients. Research in his laboratory utilizes relevant models of disease and translates these findings to critically ill patients. The NIH and the American Heart Association have supported his research, leading to over 74 peer-reviewed publications.

Dr. Poloyac has served as a reviewer for the National Institutes of Health and for numerous scientific journals. Dr. Poloyac is a Fellow of the Society of Critical Care Medicine and is a 2015-16 Fellow of the AACP Academic Leadership Fellow Program. Dr. Poloyac is committed to the advancement of pharmacy and pharmaceutical sciences both through research and through the training of the next generation of pharmacists and pharmaceutical scientists.


Critical care pharmacology and the role of cytochrome P450 enzymes in the pathogenesis of critical care illness.

RESEARCH PUBLICATIONS 2010 - 2016
Hagos FT, Daood MJ, Ocque JA, Nolin TD, Bayir H, Poloyac SM, Kochanek PM, Clark RS, Empey PE. Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine. Xenobiotica. Jun 2016; 1-8 [Epub ahead of print]. PMID: 27278858.

Kurz JE, Poloyac SM, Abend NS, Fabio A, Bell MJ, Wainwright MS; for Investigators for the Approaches and Decisions in Acute Pediatric Trial. Variation in Anticonvulsant Selection and Electroencephalographic Monitoring Following Severe Traumatic Brain Injury in Children-Understanding Resource Availability in Sites Participating in a Comparative Effectiveness Study. Pediatr Crit Care Med. May 2016. [Epub ahead of print]. PMID: 27243415.

Li J, Oberly PJ, Poloyac SM, Gibbs RB. A Microsomal Based Method to Detect Aromatase Activity in Different Brain Regions of the Rat using Ultra Performance Liquid Chromatography-Mass Spectrometry. J Steroid Biochem Mol Biol. April, 2016. [Epub ahead of print]. PMID: 27113434.

Browning M, Shear DA, Bramlett HM, Dixon CE, Mondello S, Schmid Maj KE, Poloyac SM, Dietrich WD, Hayes RL, Wang KK, Povlishock J, Tortella FC, Kochanek PM. Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. J Neurotrauma. 2015 Dec 16. PMID: 26671550.

Kochanek PM, Bramlett HM, Shear DA, Dixon CE, Mondello S, Dietrich WD, Hayes RL, Wang KK, Poloyac SM, Empey P, Povlishock J, Mountney A, Browning M, Deng-Bryant Y, Yan HQ, Jackson TC, Catania M, Glushakova O, Richieri S, Tortella FC. Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy. J Neurotrauma. 2015 Dec 16. PMID: 26671284.

Mountney A, Bramlett HM, Dixon CE, Mondello S, Dietrich WD, Wang KK, Caudle K, Empey PE, Poloyac SM, Hayes RL, Povlishock JT, Tortella FC, Kochanek PM, Shear DA. Operation Brain Trauma Therapy: Simvastatin Treatment in Traumatic Brain Injury. J Neurotrauma. 2016 Jan 20. PMID: 26541177.

Yousef KM, Balzer JR, Bender CM, Hoffman LA, Poloyac SM, Ye F, Sherwood PR. Temporal Profiles of Cerebral Perfusion Pressure After Subarachnoid Hemorrhage. J Neurosci Nurs. 2015 Aug;47(4):E2-9. PMID: 26153791

Yousef KM, Balzer JR, Bender CM, Hoffman LA, Poloyac SM, Ye F, Sherwood PR. Cerebral Perfusion Pressure and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage. Am J Crit Care. 2015 Jul;24(4):e65-71. PMID: 26134341

Shaik JS, Poloyac SM, Kochanek PM, Alexander H, Tudorascu DL, Clark RS, Manole MD. 20-Hydroxyeicosatetraenoic Acid Inhibition by HET0016 Offers Neuroprotection, Decreases Edema, and Increases Cortical Cerebral Blood Flow in a Pediatric Asphyxial Cardiac Arrest Model in Rats. J Cereb Blood Flow Metab. 2015 Jun 10. PMID: 26058691

Crago EA, Sherwood PR, Bender C, Balzer J, Ren D, Poloyac SM. Plasma estrogen levels are associated with severity of injury and outcomes after aneurysmal subarachnoid hemorrhage. Biol Res Nurs 2014; 17(%): 558-66. PMID: 25548393.

Donnelly MK, Crago EA, Conley YP, Balzer JR, Ren D, Ducruet AF, Kochanek PM, Sherwood PR, Poloyac SM. 20-HETE is associated with unfavorable outcomes in subarachnoid hemorrhage patients. J Cerebral Blood Flow Metab 2015; 35(9): 1515-22. PMID: 25920956

Omelchenko N, Roy P, Balcita-Pedicino JJ, Poloyac S, Sesack SR. Impact of prenatal nicotine on the structure of midbrain dopamine regions in the rat. Brain Struct Funct 2015; 221(4): 1939-53. PMID: 25716298.

Kochanek PM, Jackson TC, Ferguson NM, Carlson SW, Simon DW, Brockman EC, Ji J, Bayir H, Poloyac SM, Wagner AK, Kline AE, Empey PE, Clark RS, Jackson EK, Dixon CE. Emerging therapies in traumatic brain injury. Semin Neurol 2015; 35(1): 83-100. PMID: 25714870.

Jackson TC, Du L, Janesko-Feldman K, Vagni VA, Dezfulian C, Poloyac SM, Jackson EK, Clark RSB, Kochanek PM. The nuclear splicing factor RNA binding motif 5 promotes caspase activation in human neuronal cells, and increases after traumatic brain injury in mice. J Cerebral Blood Flow Metab 2015; 35(4): 655-66. PMID: 25586139

Donnelly MK, Conley YP, Crago EA, Ren D, Sherwood PR, Balzer JR, Poloyac SM. Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow and Metab. 2015; 35(2): 267-76. PMID: 25388680.

Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, Xu Z, Lih FB, DeGraff LM, Tomer KB, Jones HM, Makowski L, Huang L, Poloyac SM, Zeldin DC, Lee CR. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One. 2014; 9(10): e110162. PMID: 25310404.

Yousef KM, Balzer JR, Crago EA, Poloyac SM, Sherwood PR. Transcranial regional cerebral oxygen desaturation predicts delayed cerebral ischaemia and poor outcomes after subarachnoid haemorrhage: A correlational study. Intensive Crit Care Nurs 2014; 30(6): 246-52. PMID: 24933608.

Gallek MJ, Alexander SA, Crago E, Sherwood PR, Klamerus M, Horowitz MB, Poloyac SM, Conley Y. Endothelin-1 gene polymorphisms influence cerebrospinal fluid endothelin-1 levels following aneurysmal subarachnoid hemorrhage. Biol Res Nurs 2014; 17(2): 185-90. PMID: 24852947.

Tyurina YY, Poloyac SM, Tyurin VA, Kapralov AA, Jianfei J, Anthonymuthu TS, Kapralova VI, Vikulina AS, Jung MY, Epperly MW, Mahammeydanyi D, Klein-Seetharaman J, Jackson T, Kochanek P, Pitt, B, Greenberger JS, Vladimirov YA, Bayir H, Kagan VE. A mitochondrial pathway for biosynthesis of lipid mediators. Nature Chem 2014; 6(6): 542-52. PMID: 24848241.

Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves, Degraff LM, Lih FB, Garcia V, Shaik JS, Tomer KB, Flake GP, Falck JR, Lee, CR, Poloyac SM, Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. FASEB J. 2014; 28(7): 2915-31. PMID: 24668751.

Shaik JS, Miller TM, Graham SH, Manole MD, Poloyac SM. Rapid and simultaneous quantitation of prostanoids by UPLC-MS/MS in rat brain. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 945-946: 207-16. PMID: 24355215.

Shaik JS, Ahmad M, Li W, Rose ME, Foley LM, Hitchens TK, Graham SH, Hwang SH, Hammock BD, Poloyac SM. Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol. 2013; 305(11): H1605-13. PMC3882464. PMID: 24043255.

Liu H, Li W, Rose ME, Pascoe JL, Miller TM, Ahmad M, Poloyac SM, Hickey RW, Graham SH. Prostaglandin D2 toxicity in primary neurons is mediated through its bioactive cyclopentenone metabolites. Neurotoxicology. 2013; 39: 35-44. PMC3904641. PMID: 23973622.

Empey PE, Velez de Mendeizabal N, Bell MJ, Bies R, Kochanek PM, Adelson PD, Poloyac SM. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Crit Care Med. 2013 Oct;41(10):2379-87. PMC3783553. PMID: 23896831.

Liu H, Rose ME, Miller TM, Li W, Shinde SN, Pickrell AM, Poloyac SM, Graham SH, Hickey RW. COX2-derived primary and cyclopentenone prostaglandins are increased after asphyxia cardiac arrest. Brain Res 2013; 1519: 71-7. PMC3681205. PMID: 23624225.

Zhou T, Hu M, Cost M, Poloyac S, Rohan C. Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: Implications on microbicide research. AIDS Res Hum Retroviruses 2013; 29(11): 1496-503. PMC3809391. PMID: 23607746.

Thampatty BP, Klamerus MM, Oberly PJ, Feldman KL, Bell MJ, Tyler-Kabara EC, Adelson PD, Clark RSB, Kochanek PM, Poloyac SM. Hypothermia decreases cerebrospinal fluid asymmetric dimethylarginine levels in children with traumatic brain injury. Ped Crit Care Med 2013; 14(4): 403-12. PMID: 23439461.

Liu H, Li W, Ahmad M, Rose ME, Miller TM, Yu M, Chen J, Pascoe JL, Poloyac SM, Hickey RW, Graham SH. Increased generation of cyclopentenone prostaglandins after brain ischemia and their role in aggregation of ubiquitinated proteins in neurons. Neurotox Res. 2013; 24(2): 191-204. PMC3692569. PMID: 23355003.

Gallek M, Alexander S, Crago E, Sherwood P, Horowitz M, Poloyac S, Conley Y. Endothelin-1 and endothelin receptor gene variants and their association with negative outcomes following aneurysmal subarachnoid hemorrhage. Biol Res Nurs 2012; 15(4): 390-7. PMC3758781. PMID: 22997346.

Kim H, Crago E, Kim M, Sherwood P, Conley Y, Poloyac S, Kerr M. Cerebral vasospasm after subarachnoid hemorrhage as a clinical predictor and phenotype for genetic association study. International J Stroke. 2012; 8(8): 620-5. PMC3475757. PMID: 22568564.

Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, Lee CR. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis. 2012; 222(2): 530-6. PMC3361525. PMID: 22503544.

Poloyac SM & Empey PE. Drug dosing during hypothermia: to adjust, or not to adjust, that is the question. Ped Crit Care Med. 2013 2013 Feb;14(2):228-9. PMC3728377. PMID: 23388572.

Poloyac SM. Altered drug metabolism in critically ill children: a significant source of adverse effects? Pediatric Crit Care Med 2012; 13(1): 118-9. PMID: 22222658.

Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, and Lee CR. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab 2012; 302(5): E500-9. PMC3311291. PMID: 22185841.

Empey PE, Miller TM, Philbrick AH, Melick J, Kochanek PM, and Poloyac SM. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med. 2011; 40(4): 1221-8. PMC3307845. PMID: 22067624.

Saini SP, Zhang BJ, Niu YD, Jiang M, Gao J, Zhai YG, Uppal H, Tian H, Tortorici M, Poloyac SM, Qin W, Venkataramanan R, and Xie W. Activation of liver X receptor increases acetaminophen clearance and prevents its toxicity in mice. Hepatology 2011; 54(6): 2208-17. PMC3230770. PMID: 21898498.

Zhou J, Empey PE, Bies RR, Kochanek PM and Poloyac SM. Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism. Drug Metab Dispos. 2011; 39(12): 2209-18. PMC3226379. PMID: 21868471.

Crago EA, Thampatty BP, Sherwood PR, Kuo CWJ, Bender C, Balzer J, Horowitz M, and Poloyac SM. Cerebrospinal fluid 20-HETE is associated with delayed cerebral ischemia and poor outcomes after aneurysmal subarachnoid hemorrhage. Stroke 2011; 42(7): 1872-7. PMC3134869. PMID: 21617146.

Zhou J & Poloyac SM. The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol 2011;7(7):803-16. PMC3116014. PMID: 21473710.

Thampatty BP, Sherwood PR, Gallek MJ, Crago EA, Ren D, Hricik AJ, Kuo CW, Klamerus MM, Alexander SA, Bender CM, Hoffman LA, Horowitz MB, Kassam AB, Poloyac SM. Role of endothelin-1 in human aneurysmal subarachnoid hemorrhage: associations with vasospasm and delayed cerebral ischemia. Neurocrit Care 2011; 15(1): 19-27. PMC3134137. PMID: 21286855.

Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, and Lee CR. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos 2011; 39(1): 22-9. PMC3014271. PMID: 20947618.

Liu H, Li W, Ahmad M, Miller TM, Rose ME, Poloyac SM, Uechi G, Balasubramani M, Hickey RW, and Graham SH. Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. 2011; Neurobiol Dis. 41(2): 318-28. PMC3014436. PMID: 20933087.

Salonia R, Empey PE, Poloyac SM, Wisniewski SR, Klamerus M, Ozawa AK, Ruppel R, Feldman K, Adelson D, Clark RSB, and Kochanek PM. Endothelin-1 is increased in cerebrospinal fluid and associated with unfavorable outcomes in children after severe traumatic brain injury. 2010; J Neurotrauma. 27(10): 1819-25. PMC2953926. PMID: 20684675.

Chuang PC, Conley YP, Poloyac SM, Okonkwo DO, Ren D, Sherwood PR, Hravnak M, Alexander S. Neuroglobin genetic polymorphisms and their relationship to functional outcomes after traumatic brain injury. Journal of Neurotrauma. 2010; 27(6):999-1006. PMC2943497. PMID: 20345238.

Hostler D, Zhou JQ, Tortorici MA, Bies RR, Rittenberger JC, Kochanek PM, Callaway CW and Poloyac SM. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos. 2010; 38(5): 781-8. PMC2872942. PMID: 20164112.


EDUCATION PUBLICATIONS 2010-2016
Blouin R, Brixner D, Cutler S, Derendorf HC, Poloyac SM, Ellingrod Ringold VL, Schnellmann RG, Swaan P, Lau YS. The report of the 2012-2013 Research and Graduate Affairs Committee. Am J Pharm Educ. 2013 Oct 14;77(8):S9. PMC3806971

Robinson GFWB, Erlen JA, Rubio DM, Kapoor WN, Poloyac SM. Development, implementation, and evaluation of an interprofessional course in translational research Clin Tran Sci 2012;6(1):50-6. PMC3592569. PMID: 23399090.

Poloyac SM, Empey KM, Rohan LC, Skledar SJ, Empey PE, Nolin TD, Bies RR, Gibbs RB, Folan M, Kroboth PD. Core competencies for research training in the clinical pharmaceutical sciences. Am J Pharm Edu 2011; 75(2): 27. PMC3073101. PMID: 21519417.


BOOK CHAPTERS 2010-2016
Poloyac SM. Chapter 8: Drug and Fatty Acid Cytochrome P450 Metabolism In Critical Care. In: Xie W, ed. Drug Metabolism in Diseases. Philadelphia, PA: Elsevier. In press.

Poloyac SM. Therapeutic Hypothermia: Implications on Drug Therapy. Sadaka F. Ed. Therapeutic Hypothermia, InTech Open Access Publishers; 2013.

Poloyac SM. Pharmacologic Considerations in the Patient Undergoing Therapeutic Hypothermia. Nunnally ME Ed. Therapeutic Hypothermia in the ICU, Society of Critical Care Medicine; 2011: 35-40.

2015 - Present                     AACP Academic Leadership Fellow
2015                                       University of Pittsburgh PLS/Rho Chi Innovations in Teaching Award
2014                                       University of Pittsburgh Brenneman Scholar Award
2014                                       University of Pittsburgh Chancellors Distinguished Teaching Award
2013                                       Fellow of the American College of Critical Care Medicine
2008                                       Phi Delta Chi Outstanding Chapter Advisor Award
2003                                       Faculty Member of the Year, Academy of Students of Pharmacy University of Pittsburgh
1996 – 1999                         Pre-doctoral Fellow, American Foundation for Pharmaceutical Education

PRESENTATIONS 2010- 2016
The 21st International Symposium on Microsome and Drug Oxidations; Davis, CA. “The CYP Fatty Acid Metabolite 20-HETE and Brain Hypoperfusion:  A Target for Drug Development?” October, 2016.

Operation Brain Trauma Therapy (OBTT) Preclinical Testing for TBI Therapy Symposium. Galveston, TX. September, 2016.

The Sun Yat Sen International Graduate Student Symposium; Guangdong, China. “20-HETE as a biomarker and therapeutic target in brain injury” September, 2016.

Symposium Organizer Winter Eicosanoid Conference; Baltimore, MD. “Session IV: 20-HETE” March, 2016.

Invited Oral Debate AACP Academic Leadership Fellows Program Debate; Tampa, FL. “Change Management is a Reactive Process of Managing Resistance During Change” February, 2016.

AACP Academic Research Fellows Program Presentation; Bethesda, MD. “Leading a Research Center in Academic Pharmacy” November, 2015.

Society of Critical Care Medicine Annual Meeting; Phoenix, AZ. “Quantitative Lipidomics in Aneurysmal Subarachnoid Hemorrhage.” January 2015.

Winter Eicosanoid Conference; Baltimore, MD. “CYP Eicosanoids and Stroke: Results From a Large Cohort of Aneurysmal Subarachnoid Hemorrhage Patients.” March 2014.

American Association of Colleges of Pharmacy Annual Meeting Teachers Seminar, Chicago, Ill. “Special Session: Development of a Graduate Level Cross-Institutional Course to Foster an Understanding of Translational Sciences.” July 2013.

University of Kentucky College of Pharmacy; Lexington, KY. “Brain Cytochrome P450 Enzymes and Stroke: Translating Relevance from Rats to Humans.” February 2013.

American College of Clinical Pharmacy; Hollywood, FL. Critical Care PRN Presentation titled: “Drug Issues in Therapeutic Hypothermia.” October 2012.

North American Congress of Clinical Toxicology; Las Vegas, NV. “Too Cool for a Breakdown? Drug Metabolism in Therapeutic Hypothermia.” October 2012.

Winter Eicosanoid Conference; Baltimore, MD. “Eicosanoids in the Brain, Mediators of Injury or Protection?” March 2012.

Society of Critical Care Medicine Annual Congress 2012; Houston, TX. “Pharmacological Considerations in Patients Undergoing Therapeutic Hypothermia.” February 2012.

University of North Carolina Division of Experimental Therapeutics Seminar, Chapel Hill, NC. “Brain Cytochrome P450 Enzymes and Stroke: Discovering the Relationship with Patient Complications.” June 2011.

Samford University College of Pharmacy Symposium on Grant Funding Opportunities. Half-day symposium on Industrial and Federal Grant Mechanisms of Research Support. May 2011.

University of Minnesota College of Pharmacy End of the Year Awards Ceremony, Minneapolis, MN. “Pharmacy’s Role in Advancing Clinical and Translational Research: Examples in Critical Care Illness.” April 2011.

13th Annual Winter Eicosanoid Conference Podium Presenter. Baltimore, MD. ” HETEs and EETs on Subarachnoid Hemorrhage: Discovering the Relationship
with Patient Complications and Outcomes.” March 2011.

University of Pittsburgh Department of Environmental and Occupational Health. Pittsburgh, PA. “P450 enzymes in critical care illness: roles in drug metabolism and disease pathogenesis.” March 2011.

University of Pittsburgh Alumni Society. Pittsburgh, PA “Early Intervention in Stroke: A Life Saving Approach.” February 2011.

NHLBI and DoD Workshop: Hypothermia and Hemostasis in Severe Trauma (HYPOSTAT): A New Crossroads. Bethesda, MD, “Effects of Hypothermia on Pharmacology.” February 2011.

American Association of Colleges of Pharmacy Annual Meeting Teachers Seminar, Seattle, WA. “Interprofessional Science Education: Development and Implementation of a Course in Translational Research in the Health Sciences.” July 2010.

Society of Critical Care Medicine: Clinical Focus Conference, Pasadena, CA. “Pharmacological Considerations in Patients Undergoing Therapeutic Hypothermia.” April, 2010.

Society for Clinical and Translational Science/Association for Clinical Research Training; Annual Meeting; Washington, D.C. “Lost In Translation: The Role of the Non-Medical Researcher.” April, 2010.

University of Southern California School of Pharmacy. Clinical and Experimental Seminar Series, Pasadena, CA. “CYPs, Arachidonic Acid, and the Brain: Stroke Research from Bench to Bedside.” March, 2010.

ACTIVE - RESEARCH

HD069620 (PI: Kline)
NIH
Period of Support: 4/1/12 – 3/31/17
Understanding the Impact of Antipsychotic Drugs on Recovery after TBI

R01 NR013610A (PI: Conley; Co-I: Poloyac)
NINR
Period of Support: 9/24/12 – 6/30/17
Epigenomics of Patient Outcomes after Aneurysmal SAH

R01 HD075750 (PI: Manole; Co-PI: Poloyac)
NICHD
Period of Support: 9/10/13 – 5/31/18
CYP 450 Mediated CBF Dysregulation and Neurotoxicity in Pediatric Cardiac Arrest


NR014221 (PI: Hravnak; Co-PI: Poloyac)
NIH
Period of Support: 2/5/14 – 1/31/18
Developing Goal-Oriented Perfusion Therapy for Neurocardiac Injury in Sub-Arachnoid Hemorrhage

W81XWH-14-2-0018 (PI: Kochanek; Co-I: Poloyac)
Department of Defense
Period of Support: 5/01/2014 – 10/31/16 NCE
Operation Brain Trauma Therapy Extended

U19 AI068021-11 (Greenberger)
NIH
Period of Support: 9/1/15 8/31/16
CORE F: Signature-Directed, Sequential Delivery of Radiation Mitigators

TL1 (Reis) Role: Co-Director of Predoctoral Training
NIH
Period of Support: 07/01/2016 – 6/30/2021
University of Pittsburgh Clinical and Translational Science Institute

COMPLETED - RESEARCH

R01 NR004339 (MPI: Poloyac and Sherwood)
NINR and NINDS
Period of Support: 8/28/09 – 8/31/15 (NCE)
Determining Genetic and Biomarker Predictors of DCI and Long Term Outcomes after SAH.

R01 NS069247 (PI: Clark; Co-I: Poloyac)
NINDS
Period of Support: 9/30/09 – 6/30/15 (NCE)
Overcoming Membrane Transporters to Improve CNS Drug Therapy

R01 NS037459 (PI: Graham; Co-I: Poloyac)
NINDS
Period of Support: 9/30/09 - 7/31/13
Cyclooxygenase 2 and Ischemic Neuronal Injury

UL1 TR000005 (PI: Reis; Co-I: Poloyac)
NCATS
Period of Support: 7/1/12 – 6/30/13
University of Pittsburgh Clinical and Translational Science Institute

R01 GM088199 (PI: Lee; Co-I: Poloyac)
NIGMS
University of North Carolina at Chapel Hill
Period of Support: 8/1/09 - 5/31/14
Cytochrome P450 Derived Eicosanoids and Inflammation

NIH T32-AG021885
NIA
Period of Support: 7/1/2008 – 6/30/2012
Principal Investigator: Stephanie Studenski; Mentor: Samuel M. Poloyac
Clinical Research Training in Geriatrics and Gerontology.

R21 HD058846 01A1 (PI Hickey; Co-I Poloyac)
National Institute of Health 2,557.00
Period of Support: 4/1/09 - 3/31/11
COX2-Derived Cyclopentenone Prostaglandins Exzcerbate Hypoxic Ischemic Brain Injury by Inhibiting Protein Disulfide Isomerase and Worsening Endoplasmic Reticulum Stress

NIH R01GM073031-01A2
NIGMS/NHLBI
Period of Support: 9/01/06 – 8/31/10
Principal Investigator: Samuel M. Poloyac (25%)
Implications of Hypothermia on Hepatic Drug Metabolism.

NIH R01NS052315-01
NINDS
Period of Support: 6/15/05 – 4/30/10
Principal Investigator: Samuel M. Poloyac (35%)
The Role of 20-HETE in the Pathogenesis of Stroke.

NIH R01NR004339-05
NINR
Period of Support: 5/01/04 – 4/30/10
Principal Investigator: Mary Kerr; Co-Principal Investigator: Samuel M. Poloyac (28%)
Role of 20-HETE on Vasospasm-Induced Ischemia after SAH.

R21 DA021276 01A2
Period of Support: 9/1/07 - 7/31/09
Principal Investigator: Susan Sesack; Co-Investigator: Samuel M. Poloyac (0.6 Calendar Months)
Persistent Impact of Developmental Nicotine on Cholinergic Input to DA Cells

Competitive Medical Research Fund – Collaborative Research Grant
University of Pittsburgh Provosts Office
Period of Support: 7/1/2008 – 6/30/2010
Principal Investigator: James Tiskouris; Co-Principal Investigator: Samuel Poloyac
Investigating the Mechanism Underlying Vascular Endothelial Dysfunction in Obstructive Sleep Apnea.

NIH S10RR023461-01
NCRR
Period of Support: 4/1/2007-3/30/2008
Principal Investigator: Samuel M. Poloyac (2%)
API 4000 QTRAP.

NIH R01CA095239-01A2
NCI
Period of Support: 4/01/04 – 3/31/08
Principal Investigator: Beth Pflug; Co-Investigator: Samuel M. Poloyac (12%)
Fatty Acid Synthesis in Prostate Tumorigenesis.

Principal Investigator: Samuel M. Poloyac
Cytochrome P450 Mediated Arachidonic Acid Bioactivation and the Pathogenesis of Stroke.
Pennsylvania Heart Association, Beginning Grant in Aid. Period of Support: 07/01/02 – 06/30/04.

Principal Investigator: Samuel M. Poloyac
Potential Role of Brain 20-HETE as a Vasoconstrictive Mediator of Stroke Pathogenesis.
Pittsburgh Institute for Neurodegenerative Disorders. Period of Support: 07/01/02 – 08/30/03.

Principal Investigator: Samuel M. Poloyac
Cytochrome P450 Mediated Arachidonic Acid Bioactivation and the Pathogenesis of Stroke.
Competitive Medical Research Fund: Submitted March 11, 2002. Grant was awarded but not funded due to budgetary overlap with the previously awarded Pennsylvania Heart Association Grant.

Principal Investigator: Samuel M. Poloyac
Chemical and Neurotraumatic Alterations of Cytochrome P450 Mediated Arachidonic Acid Bioactivation in the Human Brain and CSF.
American Association of Colleges of Pharmacy: Period of Support: 12/01/01 – 12/01/03.

Principal Investigator: Samuel M. Poloyac
Potential Effects of Pentobarbital on P450-Mediated Formation of Vasoactive Arachidonic Acid Metabolites in the Brain.
University of Pittsburgh Central Research Development Fund Grant. Period of Support: 7/1/2000 - 6/30/2001.

Principal Investigator: Samuel M. Poloyac
Methods for Evaluation of Rat Brain Fatty Acid Metabolism.
University of Pittsburgh Pharmacy Associates Grant.

View CV

In some browsers, the CV link may not automatically open. You may right-click on the link to open in a new tab to view the CV file.